Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.

Journal of child neurology 2018 Vol.33(9) p. 580-586

Shah S, Calderon MD, Wu W, Grant J, Rinehart J

관련 도메인

Abstract

[BACKGROUND] The use of onabotulinumtoxin A in the pediatric population has not been evaluated for chronic migraine in a longitudinal study. This retrospective study sought to determine the efficacy and safety of onabotulinumtoxin A in prophylactic treatment of chronic migraine in the pediatric population.

[METHODS] The authors retrospectively evaluated pediatric patients who had been treated with onabotulinumtoxin A in the outpatient pain clinic for chronic migraine. Demographic data and pre- and posttreatment migraine days (frequency), pain scores (intensity), and duration of migraine episodes were collected from patient records.

[RESULTS] Ten patients were included. Median pretreatment to posttreatment headache frequency was 15.5 [8, 29.5] to 4 [2, 10] days/month ( P < .0001), durations were 8 [0, 24] to 1 [0, 7] hours ( P = .025), and intensity was 6 [4, 8] to 4 [2, 5] ( P = .0063). No serious adverse events were reported.

[CONCLUSIONS] This review over a 5-year longitudinal period demonstrates statistically significant improvement from baseline.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 onabotulinumtoxin 보툴리눔독소 주사 dict 4
시술 botox 보툴리눔독소 주사 dict 1

MeSH Terms

Adolescent; Botulinum Toxins, Type A; Child; Female; Humans; Longitudinal Studies; Male; Migraine Disorders; Neuromuscular Agents; Retrospective Studies; Treatment Outcome

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문